Pulmonary hypertension (PH) is a complex and often misunderstood condition, with significant implications for patient morbidity and mortality. This article aims to provide a comprehensive review of the fundamentals of PH for healthcare professionals.
PH is defined as an increase in mean pulmonary arterial pressure ≥ 25 mmHg at rest, as assessed by right heart catheterization. The World Health Organization (WHO) classifies PH into five groups based on etiology, clinical presentation, hemodynamic characteristics, and treatment strategy.
Regardless of the cause, the pathophysiology of PH involves three main pathways: vasoconstriction, vascular remodeling, and thrombosis. These processes lead to increased pulmonary vascular resistance, right ventricular overload, and ultimately, right heart failure.
PH often presents with nonspecific symptoms such as dyspnea, fatigue, and syncope, making diagnosis challenging. A high index of suspicion is necessary, particularly in patients with risk factors such as connective tissue disease, congenital heart disease, and chronic lung disease.
The diagnostic evaluation of PH involves a combination of clinical assessment, echocardiography, and right heart catheterization. Additional tests may include pulmonary function tests, CT scan, and ventilation-perfusion scan to identify the underlying cause.
Treatment of PH is guided by the underlying etiology and the severity of disease. Strategies include general measures, targeted drug therapy, and in severe cases, lung transplantation. Early diagnosis and treatment can significantly improve patient outcomes.
In conclusion, PH is a complex condition requiring a multidimensional approach for diagnosis and management. Healthcare professionals must have a sound understanding of the fundamentals of PH to provide optimal care for these patients.
1.
Research discovery halts childhood brain tumor before it forms
2.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
3.
'CDC Must Be Investigated'; David Lynch, Bob Uecker Die; Nasal Epinephrine Warning
4.
Increasing Access to Prostate Cancer Drugs; Reducing Toxic Emissions; FTC Files a 'Charity' Suit.
5.
Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
1.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
2.
AI-Based Cancer Follow-Up Monitoring: Transforming Survivorship Care through Intelligent Surveillance
3.
Preventing Sarcopenia During Cancer Treatment
4.
Guidance for Managing Complex Anticoagulation
5.
Unlocking the Potential of Sarclisa: A New Hope for Cancer Treatment
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XIV
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation